We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
-14.83%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$5.16B
AUM Growth
-$1.15B
Cap. Flow
+$52.2M
Cap. Flow %
1.01%
Top 10 Hldgs %
40.75%
Holding
232
New
16
Increased
80
Reduced
52
Closed
17

Top Buys

Rank Stock Value
1
BDTX icon
Black Diamond Therapeutics
BDTX
+$40.5M
2
FATE icon
Fate Therapeutics
FATE
+$37.4M
3
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$29.7M
4
ESPR
Esperion Therapeutics
ESPR
+$27.1M
5
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$25.4M

Top Sells

Rank Stock Value
1
TDOC icon
Teladoc Health
TDOC
+$63.8M
2
BMY icon
Bristol-Myers Squibb
BMY
+$54M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$26.7M
4
MRNA icon
Moderna
MRNA
+$22.7M
5
ALGN icon
Align Technology
ALGN
+$18.1M

Sector Composition

Rank Sector Weight
1 Healthcare 95.76%
2 Technology 0.56%
3 Industrials 0.54%
4 Communication Services 0.17%
5 Financials 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
STIM icon
151
Neuronetics
STIM
$120M
$616K 0.01%
325,961
– –
FAST icon
152
Fastenal
FAST
$54B
$603K 0.01%
38,598
– –
JD icon
153
JD.com
JD
$40.8B
$595K 0.01%
14,700
– –
KURA icon
154
Kura Oncology
KURA
$922M
$568K 0.01%
57,100
-100,700
-64% -$1.15M
MCK icon
155
McKesson
MCK
$98.5B
$526K 0.01%
3,892
-1,982
-34% -$290K
MSCI icon
156
MSCI
MSCI
$40B
$516K 0.01%
1,786
– –
SWKS icon
157
Skyworks Solutions
SWKS
$9.06B
$509K 0.01%
5,700
– –
CBPO
158
DELISTED
China Biologic Products Holdings, Inc.
CBPO
$486K 0.01%
4,500
– –
CLX icon
159
Clorox
CLX
$11.6B
$485K 0.01%
2,800
– –
MTD icon
160
Mettler-Toledo International
MTD
$26.8B
$483K 0.01%
700
– –
EA icon
161
Electronic Arts
EA
$52.4B
$481K 0.01%
4,800
– –
ADBE icon
162
Adobe
ADBE
$89.5B
$477K 0.01%
1,500
– –
GGG icon
163
Graco
GGG
$12.9B
$473K 0.01%
9,700
– –
ENTG icon
164
Entegris
ENTG
$19.7B
$461K 0.01%
10,300
– –
CLVS
165
DELISTED
Clovis Oncology, Inc.
CLVS
$453K 0.01%
71,200
-1,700
-2% -$13.6K
TYL icon
166
Tyler Technologies
TYL
$12.2B
$452K 0.01%
1,525
– –
A icon
167
Agilent Technologies
A
$39.1B
$444K 0.01%
6,200
-11,800
-66% -$948K
FDS icon
168
Factset
FDS
$9.05B
$443K 0.01%
1,700
– –
WSO icon
169
Watsco Inc
WSO
$14.9B
$442K 0.01%
2,800
– –
MKTX icon
170
MarketAxess Holdings
MKTX
$4.15B
$440K 0.01%
1,322
– –
POOL icon
171
Pool Corp
POOL
$6.7B
$433K 0.01%
2,200
– –
MCO icon
172
Moody's
MCO
$81.7B
$423K 0.01%
2,000
– –
BF.B icon
173
Brown-Forman Class B
BF.B
$12B
$422K 0.01%
7,600
– –
VAR
174
DELISTED
Varian Medical Systems, Inc.
VAR
$421K 0.01%
4,100
– –
ANSS
175
DELISTED
Ansys
ANSS
$419K 0.01%
1,802
– –
5 6
7
8 9

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
AI
Advent International Boston, Massachusetts $4.24B AUM 4.24% 1-Year Est. Return

Bellevue Group's Q1 2020 Portfolio in Review

As of Q1 2020, Bellevue Group held 232 positions worth $5.16B, down 18% from $6.31B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Bellevue Group's Q1 2020 filing shows 16 new, 80 increased, 52 reduced and 17 closed positions. Its largest new stake was Black Diamond Therapeutics: 1,330,000 shares worth $33.2M. The largest sale was Teladoc Health, an estimated $63.8M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 96% a quarter earlier, followed by Technology and Industrials.

  • Bellevue Group's largest Q1 2020 buy was Black Diamond Therapeutics: 1,330,000 shares worth $33.2M.
  • Bellevue Group added most to Fate Therapeutics in Q1 2020, an estimated $37.4M increase.
  • Bellevue Group's biggest Q1 2020 reduction was Teladoc Health, cutting an estimated $63.8M.
  • Bellevue Group fully exited Wright Medical Group Inc in Q1 2020, selling an estimated $17.1M.
  • Bellevue Group's ten largest holdings make up 41% of its $5.16B portfolio in Q1 2020.
  • Bellevue Group opened 16 new positions and closed 17 in Q1 2020.
  • Bellevue Group's portfolio value fell 18% quarter-over-quarter to $5.16B.

Based on Bellevue Group's 13F filing for Q1 2020, filed 14 May 2020.